BIOLINERX Ltd/S (NASDAQ:BLRX) and Prana Biotechnology (NASDAQ:PRAN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.
Volatility & Risk
BIOLINERX Ltd/S has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Prana Biotechnology has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500.
This table compares BIOLINERX Ltd/S and Prana Biotechnology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares BIOLINERX Ltd/S and Prana Biotechnology’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BIOLINERX Ltd/S||N/A||N/A||-$24.35 million||($0.27)||-3.85|
|Prana Biotechnology||$150,000.00||118.67||-$6.40 million||($0.70)||-2.86|
Prana Biotechnology has higher revenue and earnings than BIOLINERX Ltd/S. BIOLINERX Ltd/S is trading at a lower price-to-earnings ratio than Prana Biotechnology, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations for BIOLINERX Ltd/S and Prana Biotechnology, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BIOLINERX Ltd/S currently has a consensus price target of $3.00, indicating a potential upside of 188.46%. Prana Biotechnology has a consensus price target of $4.00, indicating a potential upside of 100.00%. Given BIOLINERX Ltd/S’s higher probable upside, equities analysts plainly believe BIOLINERX Ltd/S is more favorable than Prana Biotechnology.
Insider and Institutional Ownership
34.7% of BIOLINERX Ltd/S shares are held by institutional investors. Comparatively, 3.8% of Prana Biotechnology shares are held by institutional investors. 1.1% of BIOLINERX Ltd/S shares are held by insiders. Comparatively, 38.8% of Prana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Prana Biotechnology beats BIOLINERX Ltd/S on 7 of the 12 factors compared between the two stocks.
BIOLINERX Ltd/S Company Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company's other therapeutic candidates comprise BL-1040, a resorbable polymer solution for use in the prevention of ventricular remodeling; BL-9020, which is a monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; and BL-1230, a cannabinoid receptor type 2 intended as an anti-inflammatory treatment for dry eye syndrome. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.
Prana Biotechnology Company Profile
Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer's: and that is in Phase IIa clinical trials for the treatment of Huntington's diseases. The company is also developing PBT434, which is in preclinical toxicology stage for the treatment for Parkinson's disease and other movement disorders; and PBT 519 that is in preclinical toxicology stage for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company has a research collaboration agreement with Takeda Pharmaceuticals International, Inc. to slow or prevent neurodegeneration of the gastrointestinal system through PBT434, an investigational movement disorders compound. Prana Biotechnology Limited was founded in 1997 and is based in Melbourne, Australia.
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.